{"prompt": "['Amended Clinical Trial Protocol 03', '18-Oct-2019', 'EFC14153 - dupilumab', 'Version number: 1', '2.1', 'LIST OF TABLES', 'Table 1 - Eligibility interpretation for hepatitis serology', '68', 'Table 2 - Summary of handling procedures for dupilumab', '70', 'Table 3 - Summary of bioanalytical methods for dupilumab and anti-dupilumab antibody', '70', 'Table 4 - Summary of Adverse Event Reporting Instructions', '104', 'Table 5 - Summary of changes: amended protocol 02', '174', 'Property of the Sanofi Group - strictly confidential', 'Page 33', 'VV-CLIN-0528583 6.0']['Amended Clinical Trial Protocol 03', '18-Oct-2019', 'EFC14153 - dupilumab', 'Version number: 1', '3', 'LIST OF ABBREVIATIONS AND DEFINITIONS OF TERMS', 'ACQ-7 IA:', 'Asthma Control Questionnaire-Interviewer Administered, 7-question version', 'ACQ-IA:', 'Asthma Control Questionnaire-Interviewer Administered', 'AD:', 'Atopic dermatitis', 'ADA:', 'Anti-drug antibodies', 'AE:', 'Adverse event(s)', 'AESI:', 'adverse events of special interest', 'ALP:', 'Alkaline phosphatase', 'ALT:', 'Alanine aminotransferase', 'ANA:', 'Anti-nuclear antibody', 'AST:', 'Aspartate aminotransferase', 'ATS:', 'American Thoracic Society', 'bw:', 'Body weight', 'CDC-NHANES: Centers for Disease Control and Prevention-National Health and Nutrition', 'Examination Survey', 'CDMS:', 'Clinical data management system', 'CPK:', 'Creatine phosphokinase', 'CSD:', 'Clinical Study Director', 'CV:', 'Curriculum vitae', 'CV%:', 'Coefficient of variation', 'CYP:', 'Cytochrome P450', 'DMC:', 'Data Monitoring Committee', 'DRF:', 'Discrepancy Resolution Form', 'DTP:', 'Duties and Taxes paid', 'EASI:', 'Eczema area and severity index', 'EC:', 'Ethics Committee', 'ECG:', 'Electrocardiogram', 'e-CRF:', 'Electronic-case report form', 'ELISA:', 'Enzyme-linked immunosorbent assay', 'EOS:', 'End of Study', 'EOT:', 'End-of-treatment', 'EQ-5D-Y:', 'EuroQol 5-dimensions questionnaire for children', 'ERS:', 'European Respiratory Society', 'ETD:', 'Early treatment discontinuation', 'FEF:', 'Forced expiratory flow', 'FeNO:', 'Fractional exhaled nitric oxide', 'FEV1:', 'Forced expiratory volume in 1 second', 'FVC:', 'Forced vital capacity', 'GCP:', 'Good Clinical Practice', 'GINA:', 'Global initiative for asthma', 'Property of the Sanofi Group - strictly confidential', 'Page 34', 'VV-CLIN-0528583 6.0']['Amended Clinical Trial Protocol 03', '18-Oct-2019', 'EFC14153 - dupilumab', 'Version number: 1', 'GSO:', 'Global Safety Officer', 'HBc-Ab:', 'Hepatitis B core antibody', 'HBs Ab:', 'Hepatitis B surface antibody', 'HBs-Ag:', 'Hepatitis B surface antigen', 'HBV DNA:', 'Hepatitis B virus DNA', 'HCRU:', 'healthcare resource utilization', 'HCV-Ab:', 'Hepatitis C virus antibody', 'HIV:', 'Human immunodeficiency virus', 'HLGT:', 'high-level group term', 'HLT:', 'high level term', 'HRQoL:', 'Health related quality of life', 'HVC RNA:', 'Hepatitis C virus RNA', 'IAF:', 'Informed assent form', 'ICF:', 'Informed consent form', 'ICH:', 'The International Conference on Harmonisation of Technical Requirements for', 'Registration of Pharmaceuticals for Human Use', 'ICS:', 'Inhaled corticosteroids', 'IEC:', 'Independent Ethics Committee', 'IgA:', 'Immunoglobulin A', 'IgE:', 'Immunoglobulin E', 'IgG:', 'Immunoglobulin G', 'IgM:', 'Immunoglobulin M', 'IL:', 'interleukin', 'IL-13:', 'Interleukin-13', 'IL-4:', 'Interleukin-4', 'IMP:', 'Investigational medicinal product', 'IRB:', 'Institutional Review Board', 'ITT:', 'intent-to-treat', 'IVIG:', 'Intravenous immunoglobulin', 'IVRS:', 'Interactive voice response system', 'IWRS:', 'Interactive web response system', 'LABA:', 'Long-acting \u00df2 agonist', 'LAMA:', 'Long acting muscarinic antagonist', 'LFT:', 'Liver function tests', 'LOAC:', 'Loss of Asthma Control', 'LTRA:', 'Leukotriene receptor antagonist', 'MCID:', 'Minimal clinically important difference', 'MDI:', 'Metered-dose inhaler', 'MID:', 'Minimally important difference', 'MMRM:', 'Mixed-effect model with repeated measures', 'NIMP:', 'Non-investigational medicinal product', 'NRS:', 'Numerical Rating Scale', 'PACQLQ:', \"Pediatric Asthma Caregiver's Quality of Life Questionnaire\", 'PAQLQ(S)-IA', 'Paediatric Asthma Quality of Life Questionnaire with Standardised Activities-', 'Interviewer Administered', 'PBMC:', 'Peripheral blood mononuclear cells', 'Property of the Sanofi Group - strictly confidential', 'Page 35', 'VV-CLIN-0528583 6.0']\n\n###\n\n", "completion": "END"}